Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

被引：7
|
作者：
Grant, Christopher [1 ]
Nagasaka, Misako [1 ,2 ]
机构：
[1] Univ Calif Irvine, Med Ctr, Dept Med, Orange, CA USA
[2] Univ Calif Irvine, Med Ctr, Dept Med, Div Hematol & Oncol, Orange, CA USA
来源：
CANCER TREATMENT REVIEWS | 2024年 / 126卷
关键词：
Neoadjuvant targeted therapy; Perioperative targeted therapy; NEOADAURA; EGFR-mutant; Osimertinib; TYROSINE KINASE INHIBITOR; OPEN-LABEL; PHASE-III; OSIMERTINIB; GEFITINIB; RESISTANCE; ERLOTINIB; 1ST-LINE;
D O I：
10.1016/j.ctrv.2024.102724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Effect of EGFR-TKI targeted therapy in patients with advanced non-small cell lung cancer
    Yan, Meihao
    Chen, Shanshan
    Fan, Hongtao
    Hong, Yuancheng
    Huang, Wencheng
    Lin, Zhimin
    Lai, Zhangchao
    Hong, Liyue
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (11): : 7916 - 7923
  • [3] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [5] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [6] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [7] The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
    Xu Yufen
    Song Binbin
    Chen Wenyu
    Liu Jialiang
    Yang Xinmei
    SPRINGERPLUS, 2016, 5
  • [8] Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
    Wang, Haocheng
    Yang, Xue
    Sun, Yang
    Li, Yanan
    Dong, Ya
    Shan, Dongfeng
    Yu, Zhuang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (01) : 372 - 381
  • [9] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    Oncology and Translational Medicine, 2015, 1 (01) : 20 - 25
  • [10] REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Yamauchi, Hiroyoshi
    Nakayama, Masayuki
    Yamamoto, Shinichi
    Saito, Tatsuya
    Okuyama, Akiko
    Mato, Naoko
    Yamasawa, Hideaki
    Suzuki, Takuji
    Bando, Masashi
    Hagiwara, Koichi
    RESPIROLOGY, 2017, 22 : 242 - 242
12345